A Phase 1, Open-label, Single Dose Study to Assess the Absorption, Metabolism, and Excretion of [14C]BMS-986435 in Healthy Male Participants
Latest Information Update: 29 May 2023
At a glance
- Drugs MYK 224 (Primary)
- Indications Hypertrophic cardiomyopathy
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 24 May 2023 Status changed from recruiting to completed.
- 17 Mar 2023 Status changed from not yet recruiting to recruiting.
- 18 Jan 2023 New trial record